Master in silico drug design (RUS)

Language(s) of instruction: English

Length of study: 2 Years

Partner: Sechenov University, Russia

Course Location:

As part of this double degree, Russian students will do their 1st year of master (S1+S2) at the University of Sechenov and S3 at Université Paris Cité. Students will spend their S4 doing their intership at the University of their choice (Paris or Sechenov). As part of the double degree, students from Paris will be able to do their semester 2 and / or their semester 4 internship at Sechenov University.

Degrees awarded:

Master degree Bio-informatics in the speciality “In silico Drug Design – Macromolecule Modeling” from Université Paris Cité;

Master degree in “Information systems and technologies”, speciality “Computer modelling in pharmacology” of Sechenov University.

Entry Requirements: Students with bachelor or equivalent degree in bioinformatics or chemistry (180 ECTS credits) in bioinformatics or chemistry or biochemistry having minimum knowledge in the field of informatics or students with an equivalent degree in physical, biochemistry, pharmacy, chemical, physical and mathematical sciences, upon successfully passed Université Paris Cité entrance examination.

Language pre-requisites: B2 level of French and English

Note: Due to the current conflict, the university has currently suspended its agreements with the Russian partner universities. The pedagogical team consequently suspended its partnership with the University of Sechenov.

Course overview

The «ISDD-Macromolecules» course focuses on the computational modelling of biological macromolecule targets and their interactions with drugs and other chemical molecules. This course is aimed more particularly at students with a background in biology/biochemistry, bioinformatics, or the biomedical field (or chemists with the required knowledge in biology), who wish to acquire in-depth knowledge in modelling therapeutic macromolecules. It includes participation by international experts, and a semester of study and/or internship abroad.

This master trains professionals from the private and public sectors, who are involved in research through in silico approaches in the field of therapeutic innovation, oriented towards obtaining therapeutic targets, and the development of pharmacological molecules. The skills acquired by students in the various modules and their joint projects, offer them opportunities in the initial phase of rationalisation and optimisation of the discovery of new molecules with the potential to become the drugs of the future, and in the control (and/or development) of methodologies and software to accelerate the process of finding new molecules for potential drugs. It offers thus many opportunities with a very strong demand in the job market.

Skills and competencies developed
  • Research of bioactive compounds and research in preparation for further study at doctoral level
  • Training on how to navigate the chemical elements rationally in order to facilitate the discovery of bioactive molecules necessary for an understanding of Life and the prediction of the impact of xenobiotics on humans and the environment
  • At the end of the Master’s, students should be able to participate or lead projects in silico drug design in pharmaceutical companies, medicinal chemistry companies or among sellers of chemicals or specialized software.


Ms. Cédric de Cassan, administrative coordinator:
Prof. Anne-Claude Camproux, pedagogical coordinator: